MAAT INDEX

CLAIM #56229 · Thermo Fisher Scientific Inc (TMO) · 2022Q4 earnings call · Feb 1, 2023 · due Mar 31, 2023

From a foreign exchange standpoint while a slight tailwind for the year as a whole in Q1, FX is expected to be a year-over-year headwind of approximately $200 million of revenue and $80 million of adjusted operating income.

Stephen Williamson · CFO

PENDING
graded after results covering Mar 31, 2023 are reported

How to check this claim

Look at: Q1 2023 year-over-year impact of foreign exchange on revenue and adjusted operating income

It came true if: Q1 2023 FX impact reported as a net tailwind to revenue and adjusted operating income year-over-year (positive direction, consistent with 'slight tailwind for Q1')

Where: Company Q1 2023 earnings release and earnings call commentary (FX impact disclosure)

In context

e approximately 388 million shares. We’re assuming that we’re return approximately $540 million of capital to shareholders this year through dividends. And as is our normal convention, our guidance does not assume any future acquisitions or divestitures. And finally, I wanted to touch on quarterly phasing for the year. Revenue adjusted operating margin and adjusted EPS are all expected to ramp up as we go through the year. This is due to several factors. Core organic revenue growth is expected increase as we go through the year, largely due to the comps related to vaccines and therapies as well as the expected phasing of economic activity in China. The impact of the runoff in testing revenue is most pronounced in Q1 and the benefits of the offsetting cost actions are spread over the year. From a foreign exchange standpoint while a slight tailwind for the year as a whole in Q1, FX is expected to be a year-over-year headwind of approximately $200 million of revenue and $80 million of adjusted operating income. Below the line, net interest expense is expected to decrease during the year as we generate free cash flow and interest on that cash build. Putting all this together for Q1, we expect core organic revenue growth to be in the mid-single digits. Adjusted operating margin to be slightly lower than Q4 2022 and adjusted EPS to be just over 20% of the full year total. So to wrap up, we had an excellent 2022 and we’re really well positioned to continue to deliver differentiated performance for all our stakeholders in 2023. I look forward to updating you on our progress as we go through the year. With that, I'll turn the call back over to Raf. Rafael Tejada: Thank you, Stephen. Operator, we're ready for the Q&A portion of the call. Operator: Thank you. [Operator Instructions] The first question w

Verify independently

SEC filings for TMO · Claim quote is verbatim from the 2022Q4 earnings call.